Post-approval Studies for Rare Disease Treatments and Orphan Drugs
Drug development involves a multi-stage process of drug discovery, animal studies and human clinical trials to assess the safety and efficacy of new medications. Rare disease drug development involves a much smaller number of affected patients, a predominance of pediatric patients and more complicated disease presentation. Post-approval studies are designed to address several limitations associated with the rare disease clinical trials.
National and international regulatory agencies in the US and Europe have adopted similar approaches to requirements post-approval data for rare diseases and orphan drug indications. The US FDA published guidance in 2011 and the European Medicines Agency in 2015.
Post-approval studies for rare diseases include observational studies, pragmatic trials and randomized controlled studies. Observational studies include both original data collection studies and the use of secondary data (retrospective studies). Original data collection can address limitations of retrospective studies resulting from incomplete information in secondary data sources. Disease registries focus on detail about a broad range of patients with a rare disease while product-related registries focus on specific health care outcomes associated with a single product and may incorporate a comparator of an alternative therapy or therapies.
Rare disease patients can be difficult to find and enroll in a registry using conventional physician based driven recruitment. The study process also needs to recognize changes in the patient’s disease and lifestyle and adapt both the study design and methods over time. Many rare diseases have strong patient advocacy groups that can in aid the design and execution of rare disease registries.
KeywordsRare diseases Orphan drugs Post-approval studies Phase 4 studies Post-marketing surveillance Regulatory requirements Pharmacovigilance Pharmacoepidemiology Risk evaluation and mitigation strategies
- 2.EMA Guidance – Good Pharmacovigilance Practices Module V Risk Management Systems 28 April 2014Google Scholar
- 3.EMA – Good Pharmacovigilance Practices Module VIII Post-Authorization Safety Studies 20 February 2012Google Scholar
- 4.EMA Guidance – Good Pharmacovigilance Practices Module XVI: Risk Minimization Measures – Selection of Tools and Effectiveness Indicators: 28 April 2014Google Scholar
- 5.EMA Guidance – Safety and Efficacy Follow-up of Advanced Therapy Medicinal Products – Draft Guidance 2008Google Scholar
- 6.FDA Guidance Document – Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications – September 2009Google Scholar
- 7.FDA Guidance Document – Good Pharmacovigilance Practices and Pharmaco-epidemiologic Assessment (Pharmacovigilance Guidance) – March 2005Google Scholar
- 8.FDA Guidance Document- Post-Marketing Studies and Clinical Trials — Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act – April 2011Google Scholar
- 9.FDA Guidance Document – Medication Guides – Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) – November 2011Google Scholar
- 10.Pollack A July 14, 2007 Pricing pills by the results. New York Times. Available at: http://www.nytimes.com/2007/07/14/business/14drugprice.html